Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen

HIV疫苗和其他预防策略的开发依赖于在临床前研究中使用非人灵长类动物，以促进有效的AIDS疫苗候选物的开发，并促进有效的局部杀微生物剂和其他预防方式或基于免疫的疗法的开发。NIAID猴疫苗评价单位（SVEU）合同应提供非人灵长类动物资源，主要支持艾滋病疫苗的临床前评价。SVEU进行研究，以支持广泛的研究人员正在开发的疫苗。这些研究补充了NIAID支持的基础疫苗研究和疫苗评估研究，这些研究通过R 01（疫苗启动研究）赠款、HIVRAD（艾滋病毒疫苗研究和设计计划）赠款、IPCAVD（临床前-临床艾滋病疫苗开发综合）赠款和NHP财团赠款资助。SVEU还对公司或其他研究人员提供的候选疫苗进行研究。主要活动是研究评估对三聚体稳定的gp 120免疫原的免疫反应。

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers.The primary activity is to studies to evaluate Immune responses to a trimerically stabilized gp120 immunogen.